| FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats | Frank Vinluan | 10/09/20 | Europe |
| Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China | Frank Vinluan | 09/30/20 | New York |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue | Frank Vinluan | 09/09/20 | National |
| AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase | Frank Vinluan | 09/04/20 | National |
| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial | Sarah de Crescenzo | 08/27/20 | New York |
| AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact | Frank Vinluan | 08/07/20 | Boston |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| AbbVie Walks From Voyager R&D Pact Spanning Alzheimer’s, Parkinson’s | Frank Vinluan | 08/04/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs | Sarah de Crescenzo | 07/09/20 | San Diego |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| Eye Inflammation Dooms AbbVie Wet AMD Drug to an FDA Rejection | Frank Vinluan | 06/26/20 | National |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug | Frank Vinluan | 06/18/20 | Seattle |
| Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs | Sarah de Crescenzo | 06/18/20 | San Diego |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes | Frank Vinluan | 06/11/20 | Boston |
| AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal | Sarah de Crescenzo | 06/10/20 | National |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Chinook, Aduro Merger Plan Sets Up New Kidney Disease-Focused Biotech | Frank Vinluan | 06/02/20 | Seattle |
| AbbVie Wins First FDA Approval of Drug to Treat Uterine Fibroid Bleeds | Frank Vinluan | 05/29/20 | National |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies | Frank Vinluan | 05/12/20 | San Francisco |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans | Frank Vinluan | 04/27/20 | New York |
| CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas | Frank Vinluan | 03/24/20 | San Francisco |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
